Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pain drug lyrica put to the test for rare limb condition – but trial stalls

NCT ID NCT00891397

Symptom relief Sponsor: McMaster University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding pregabalin (Lyrica) to standard treatment could reduce pain and improve function in people with complex regional pain syndrome (CRPS) of the upper limb. Only 14 adults were enrolled before the trial was stopped early. The goal was to see if the drug provided meaningful pain relief compared to a placebo sugar pill.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pregabalin (Lyrica)
What this could lead to
If it worked, this could point toward a way to reduce pain and improve hand/arm function for people with complex regional pain syndrome.
What could go wrong
The trial was terminated early and only enrolled 14 people, so results are very limited. It is unclear if pregabalin offers real benefit over placebo for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

14 people

The number who actually took part.

Started

Nov 2007

Finished

Oct 2010

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with CRPS Type I as per the IASP (International Association for the Study of Pain) criteria which states presence of an initiating noxious event, or cause for immobilization * Evidence at some point of swelling, color change, hot/cold/sweaty sensation and no other condition which can account for the pain and dysfunction of the upper limb * Men or women between ages 18-65 year old * Women should not be pregnant or breast feeding * No change in treatment for 4 weeks prior to recruitment * Pain scores of 4/10 on a verbal analogue scale Exclusion Criteria: * Patients with a neurologic disorder unrelated to CRPS * Patients who are already on pregabalin * Patients with renal impairment whose creatinine clearance is less than 60 ml/min * Patients with congestive heart failure who are also diabetic and taking thiazolidinedione medication like rivoglitazone * Unstable psychiatric history * Patients with another problem with equal or worse pain * Unstable medical condition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Complex regional pain syndrome type I are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

complex regional pain syndrome complex regional pain syndrome type 1 Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Complex regional pain syndromes

Contacts and locations

Locations

  • Hamilton General Hospital

    Hamilton, Ontario, L8L 2X2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.